APA (7th ed.) Citation

Tsutani, Y., Goldman, J. W., Dacic, S., Yatabe, Y., Majem, M., Huang, X., . . . He, J. (2023). Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical lung cancer, 24(4), 376-380. https://doi.org/10.1016/j.cllc.2023.02.002

Chicago Style (17th ed.) Citation

Tsutani, Yasuhiro, Jonathan W. Goldman, Sanja Dacic, Yasushi Yatabe, Margarita Majem, Xiangning Huang, Allen Chen, Toon van der Gronde, and Jie He. "Adjuvant Osimertinib Vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2." Clinical Lung Cancer 24, no. 4 (2023): 376-380. https://doi.org/10.1016/j.cllc.2023.02.002.

MLA (9th ed.) Citation

Tsutani, Yasuhiro, et al. "Adjuvant Osimertinib Vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2." Clinical Lung Cancer, vol. 24, no. 4, 2023, pp. 376-380, https://doi.org/10.1016/j.cllc.2023.02.002.